| Name | Title | Contact Details |
|---|
We bring the hospital to you! We deliver advanced medical care to where and when patients and their families want and need it. The Medically Home Program gives you more care over a longer period of time. We know getting well from a hospital-level illness or surgical procedure takes weeks, not days. With the Medically Home Program, you get the time you need - at home - with a single care team available to you the entire time. One of the secrets to getting better is being involved in – and understanding – your own care. The more time you and your family spend with our clinical care team, the more tools you will have to be get better. We know it can be hard for you to deal with medication, nutrition, stress and other health issues. The relationship we build during our time together will help us support your goal of getting better. Having the time to get to know you and your family is a big part of how we deliver care, because you really matter.
Healthcare Admin Partner is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Healthcare Admin Partner is based in Media, PA. You can find more information on Healthcare Admin Partner at www.hapusa.com
Eastern Area Specialty Transport is a Winchester, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Southern Hills Medical Center is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.